Edition:
India

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

5.02USD
23 Apr 2018
Change (% chg)

$-0.10 (-1.95%)
Prev Close
$5.12
Open
$5.15
Day's High
$5.20
Day's Low
$5.02
Volume
33,467
Avg. Vol
507,019
52-wk High
$8.61
52-wk Low
$1.41

Select another date:

Sat, Apr 7 2018

BRIEF-Proteostasis Therapeutics Files For Mixed Shelf Of Up To $100 Mln

* PROTEOSTASIS THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: [https://bit.ly/2H14NPj] Further company coverage:

BRIEF-Proteostasis Receives FDA Fast Track Designation For Triple Combination Program In Patients With Cystic Fibrosis

* PROTEOSTASIS THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR TRIPLE COMBINATION PROGRAM IN PATIENTS WITH CYSTIC FIBROSIS

BRIEF-Proteostasis Announces Proposed Public Offering Of Common Stock

* PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Proteostasis Therapeutics Expects Cash, Cash Equivalents,Short-Term Investments To Be Enough To Fund Its Operating Expenses

* PROTEOSTASIS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Proteostasis Therapeutics Sees Cash, Cash Equivalents Balance As Of Dec 31, Sufficient To Fund Operations Into Early 2019​

* PROTEOSTASIS THERAPEUTICS INC - CO ESTIMATES CASH, CASH EQUIVALENTS BALANCE AS OF DEC 31, 2017, SUFFICIENT TO FUND OPERATIONS INTO EARLY 2019​ Source text: (http://bit.ly/2FWFOfk) Further company coverage:

BRIEF-Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share

* PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies

* PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS

BRIEF-Proteostasis Therapeutics Q3 loss per share $0.56

* Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update

BRIEF-Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D

* Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​

Select another date: